Related Experiment Video
Updated: Jan 1, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Recalcitrant Issues and New Frontiers in Nano-Pharmacology
Vinay Bhardwaj1, Ajeet Kaushik2, Ziad M Khatib3
1Department of Biomedical Engineering, The College of New Jersey, Ewing, NJ, United States.
Abstract:
Packaging of old pharma drugs into new packaging "nanoparticles" is called nano-pharmacology and the products are called nano-based drugs. The inception of nano-pharmacology research and development (R&D) is marked by the approval of the first nano-based drug Doxil® in 1995 by the Food and Drug Administration. However, even after more than two decades, today, there are only ∼20 nano-based drugs in the market to treat cancers and brain diseases. In this article we share the perspectives of nanotechnology scientists, engineers, and clinicians on the roadblocks in nano-pharmacology R&D. Also, we share our opinion on new frontiers in the field of nano-pharmacology R&D that may allow rapid and efficient transfer of nano-pharma technologies from R&D to market.
Related Concept Videos
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Drug Discovery: Overview
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Drug Clearance: Overview
Drug clearance is not limited to renal excretion but encompasses all organs involved in drug elimination, including...
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...

